asmondemand

ICAAC in Washington, D.C. 2014

Researchers have created a synthetic DNA analog that can bind to and silence the gene responsible for NDM-1, a severe form of antibiotic resistance that can make some bacteria resistant to almost all antibiotics.

Recognizing the importance of the public health emergency of the Ebola outbreak in western Africa, the organizers of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) the annual infectious diseases meeting of the American Society for Microbiology (ASM) added 3 new presenters to the program to speak on the disease.

Saturday, 09 August 2014 13:52

New Targets for SARS/MERS Drugs - ICAAC 2014

Posted by:
There are currently no antiviral agents approved for treatment of MERS or SARS. Researchers discuss late-breaking research on a newly identified candidate compound as well as other options for treatment currently in the pipeline.
Using tracer viruses, researchers found that contamination of just a single doorknob or table top results in the spread of viruses throughout office buildings, hotels, and health care facilities. Within 2 to 4 hours, the virus could be detected on 40 to 60 percent of workers and visitors in the facilities and commonly touched objects.

Rapid detection of antibiotic resistance is vital in assessing the appropriate antibiotic therapy for an infection. Participants present data on two new inexpensive tests to detect antibiotic resistance markers within hours or even minutes.

A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole against invasive mold disease in cancer patients with less adverse effects. Researchers present phase III data on this new drug.

Monday, 09 June 2014 14:20

New Single-Dose Influenza Drug - ICAAC 2014

Posted by:

An analysis of phase 2 and phase 3 clinical trials shows that a single injected dose of the neuraminidase inhibitor (NAI) paramivir is safe and effective at alleviating influenza symptoms including fever and viral shedding when administered within 48 hours of the onset of symptoms. Researchers present data on what may be the first new influenza drug in over a decade.

For patients who acquire an infection while in the hospital, each day of hospitalization increases the risk that the infection will be caused by a drug-resistant bacterium. Researchers present data showing that that risk increases by as much as 1% each day.
Antibiotic stewardship programs, which promote the appropriate use of antibiotics in hospitals and other healthcare centers, can not only lead to reduction in antibiotic use with no adverse effects but can also lead to significant savings, over $600,000 annually in the case of one New York Hospital. Participants will discuss case studies of two such programs.

TPL_asm2013_SEARCH

86